Proven Impact
The Tappt™ platform powering SureDose has been validated through multiple peer-reviewed studies and clinical trials, demonstrating significant improvements in medication adherence and patient outcomes.90.7%
Average medication adherence rate
58.6%
Reduction in medication-related side effects
44.5%
Improvement in symptom severity scores (PRO)
83.5%
Patient engagement over 1 year
92%
Patient satisfaction score
75.1
System Usability Score (exceeds 68 benchmark)
Published Research
ASSIST Study (Inflammatory Bowel Disease)
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With IBD TherapyStudy Details
Study Details
- Lead Researchers: Jordan Axelrad, MD, MPH; Tamar Sapir, PhD; Sara Horst, MD; Raymond Cross, MD
- Published: JMIR Research Protocols (2022), American Journal of Gastroenterology (2024)
- Award: Award-winning presentation at American Telemedicine Association Annual Meeting 2025
- Study ID: Protocol Publication
- Demonstrated significant improvement in adherence rates for IBD medications
- Real-time monitoring enabled early intervention for side effects
- Patients reported high satisfaction with tap-to-confirm simplicity
- Axelrad J, Long M, Horst S, et al. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2022;11(12):e40382.
- Axelrad J, Sapir T, Horst SN, et al. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With Inflammatory Bowel DiSease Therapy: Updates From the ASSIST Study. Am J Gastroenterol 2024;119(10S):S865-S867.
SMART Reach Trial (Breast Cancer)
Systematic Monitoring and Adherence Realization for Treatment in Hormone Receptor-Positive Breast CancerStudy Details
Study Details
- Lead Researchers: Sara Arshad, PhD; Tamar Sapir, PhD; Jane Meisel, MD; Ilana Graetz, PhD
- Presented: Pharmacy Quality Alliance Annual Meeting 2025 (Gold Medal Winner)
- Published: Journal of the American Pharmacists Association (2025)
- Also Presented: American Society of Clinical Oncology (ASCO) 2025
- Improved adherence to CDK4/6 inhibitors in breast cancer patients
- Identified role of social determinants of health in medication adherence
- Remote monitoring enabled personalized intervention strategies
- Arshad S, Sapir T, Carter J, et al. Feasibility Trial of the Systematic Monitoring and Adherence Realization for Treatment in Hormone Receptor-Positive Breast Cancer (SMART Reach). J Am Pharm Assoc 2025;65(3):102398. [Gold Medal Winner]
- Sapir T, Beckmann L, Arshad S, et al. The Role of Social Determinants of Health in Medication Adherence for CDK4/6 Inhibitors in Breast Cancer: Insights From a Remote Monitoring Tool. J Am Pharm Assoc 2025;65(3):102398.
- Meisel J, Sapir T, Graetz I, et al. Improving adherence to CDK4/6 inhibitors in breast cancer through remote therapeutic monitoring with real-time adherence tracking and actionable alerts. JCO 2025;43:e12520.
HIV Care Engagement Study
Improving ART Adherence and HIV Care Engagement Through Multi-Faceted InterventionsStudy Details
Study Details
- Lead Researchers: Lisa Hightow-Weidman, MD, MPH; Tamar Sapir, PhD; Kelly Pillinger, PharmD, BCIDP
- Presented: IDWeek, October 2025
- Study Focus: Antiretroviral therapy (ART) adherence in HIV patients
- Multi-faceted approach combining NFC tracking with patient support
- Improved engagement with HIV care services
- Real-time monitoring enabled rapid response to adherence gaps
- Hightow-Weidman L, Sapir T, Molloy L, et al. Improving ART Adherence and HIV Care Engagement Through Multi-Faceted Interventions. IDWeek 2025. Abstract #2112329.
Ongoing Clinical Trials
MONITOR Study (Inflammatory Bowel Disease)
Study of Efficacy and Adherence to Subcutaneous Vs. Intravenous Vedolizumab Using Remote Monitoring
- ClinicalTrials.gov ID: NCT06750731
- Status: Active
- Focus: Comparing adherence between different administration routes with remote monitoring support
HCV Tappt Adherence Study
Hepatitis C Treatment Adherence Monitoring
- ClinicalTrials.gov ID: NCT06263829
- Status: Active
- Focus: Improving adherence to Hepatitis C therapy through real-time tracking
Renal Pelvic Denervation Pilot
Renal Pelvic Denervation Adherence Trial
- ClinicalTrials.gov ID: NCT07005050
- Status: Active
- Focus: Post-procedure medication adherence monitoring
Case Management Applications
Remote Therapeutic Monitoring (RTM)
Growth of RTM Opportunities
Moreo K, Sapir T. Growth of Remote Therapeutic Monitoring Lands New Opportunities for Case Management. Prof Case Manag 2024;29(2):63-69.This publication explores how Tappt’s PDURS classification opens new reimbursement opportunities for pharmacists and case managers through Medicare RTM codes.
Patient Testimonials
From Published Research:
“I finally haven’t felt so alone taking this medicine.” — Patient with Breast Cancer (SMART Reach Trial)
“With Tappt, we can now add another layer of adherence monitoring to make sure our clients get the right meds at the right time.” — Pharmacy Owner (ASSIST Study)
Industry Recognition
Award-Winning Presentations
- Gold Medal Winner: PQA Annual Meeting 2025 (SMART Reach)
- Award Winner: ATA Annual Meeting 2025 (ASSIST Study)
Media Coverage
- Refresh Miami: “This smart label for medications can improve healthcare outcomes at scale” (September 2022)
Regulatory Status
Compare to Industry Standards
| Metric | Industry Average | SureDose (Tappt) | Improvement |
|---|---|---|---|
| Medication Adherence | ~50% | 90.7% | +81% |
| Patient Retention (1 year) | ~40-60% | 83.5% | +39-109% |
| Patient Satisfaction | ~70-80% | 92% | +15-31% |
| System Usability (SUS) | 68 (benchmark) | 75.1 | +10% |
Next Steps
Implementation Guide
Learn how to start using SureDose in your practice
RTM Billing Guide
Understand reimbursement opportunities
Want to participate in research? Contact our clinical team to learn about ongoing studies and partnership opportunities.